Watch SBFMW. Know when insiders buy.
One email the day a filing lands. Free.
SBFMW
Sunshine Biopharma Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM $35.3M −2.7%NET INCOME −$5.8MNET CASH $17.7M52W —SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $9.3M | −1.6% | 26.2% | −$1.6M | −$1.6M | — | -1.15 | −$918K | $7K | −$925K | Aug 13 |
| Q1 2026 · Mar 31 | $8.1M | −9.1% | 27.0% | −$1.4M | −$1.2M | — | -0.25 | −$2.1M | $5K | −$2.1M | May 13 |
| Q4 2025 · Dec 31derived | $8.6M | −10.6% | 35.3% | −$1.8M | −$2.1M | — | -0.46 | −$1.6M | −$1K | −$1.6M | Apr 3 |
| Q3 2025 · Sep 30 | $9.4M | +11.6% | 32.6% | −$1.1M | −$884K | — | -0.19 | −$747K | $8K | −$755K | Nov 13 |
| Q2 2025 · Jun 30 | $9.4M | +1.2% | 36.4% | −$2.1M | −$1.8M | — | -0.82 | −$1.3M | $160K | −$1.4M | Aug 13 |
| Q1 2025 · Mar 31 | $8.9M | +18.0% | 30.7% | −$1.3M | −$1.2M | — | -0.44 | −$1.7M | $7K | −$1.7M | May 13 |
| Q4 2024 · Dec 31derived | $9.6M | +24.9% | 32.2% | −$2M | −$2.2M | — | 6.29 | −$3.4M | $103K | −$3.5M | Apr 3 |
| Q3 2024 · Sep 30 | $8.4M | +41.6% | 34.0% | −$1.1M | −$1.2M | — | -0.94 | −$1.4M | $517K | −$1.9M | Nov 13 |
| Q2 2024 · Jun 30 | $9.3M | — | 25.3% | −$1.3M | −$494K | — | -43.48 | −$4.6M | $975K | −$5.6M | Aug 12 |
| Q1 2024 · Mar 31 | $7.5M | — | 31.2% | −$1.4M | −$1.3M | — | -2.00 | −$3.2M | $63K | −$3.2M | May 15 |
| Q4 2023 · Dec 31derived | $7.7M | — | 33.4% | −$1.2M | −$1.3M | — | -85.65 | −$2.7M | −$382K | −$2.3M | Apr 1 |
| Q3 2023 · Sep 30 | $6M | — | 33.4% | −$779K | −$651K | — | -50.72 | −$457K | $10K | −$467K | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $36.3M | 33.8% | −$6.2M | −$6M | -16.5% | -1.44 | −$5.3M | $174K | −$5.5M | $0 | — |
| FY2024 · to Dec 31 | $34.9M | 30.6% | −$5.8M | −$5.1M | -14.7% | -7.32 | −$12.5M | $1.7M | −$14.2M | $3.1M | — |
| FY2023 · to Dec 31 | $24.1M | 34.6% | −$4.8M | −$4.5M | -18.7% | -351.36 | −$8.8M | $82K | −$8.9M | $541K | — |
| FY2022 · to Dec 31 | $4.3M | 39.0% | −$27M | −$26.7M | -615.4% | -1.76 | −$5.2M | $194K | −$5.4M | — | — |
| FY2021 · to Dec 31 | $228K | 48.4% | −$2.4M | −$12.4M | -5444.4% | -4.76 | −$1.8M | $0 | −$1.8M | — | — |
| FY2020 · to Dec 31 | $71K | 63.8% | −$577K | −$2.8M | -3898.7% | -2.73 | −$657K | $1K | −$658K | — | — |
Every number comes from Sunshine Biopharma Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.